1480724-61-5
Chemical Structure
Vosoritide
Synonym(s): BMN 111
- CAS No.: 1480724-61-5
- Formula:C176H290N56O51S3
- Molecular Weight:4102.73
IUPAC Name: 4,9-bis(5-bromothiophen-2-yl)-2,7-bis(2-octyldodecyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone
SMILES: O=C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CNC=N1)C(N2[C@@H](CCC2)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CSSC[C@@H](C(O)=O)NC4=O)C(N[C@@H](CC5=CC=CC=C5)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CO)C(NCC(N[C@@H](CC(C)C)C(NC4)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]6NCCC6
Biological Activity: Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vosoritide | 99.89% | Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Duggan S. Vosoritide: First Approval. Drugs. 2021 Nov;81(17):2057-2062. [Content Brief]
- [2]. Shuhaibar LC, et al. Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth. JCI Insight. 2021 May 10;6(9):e141426. [Content Brief]
- [3]. Lorget F, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012 Dec 7;91(6):1108-14. [Content Brief]
